The role of immunotherapy prior to liver transplantation in advanced or down-staged HCC – timing of transplants, selection of patients, and hurdles to overcome with immunosuppression

作者
Parissa Tabrizian,Albert Chan,Rebecca Marino,Giudicelli Héloïse,Allan Hoi-Kin Lam,Amandine Manon
出处
期刊:International Journal of Surgery [Wolters Kluwer]
标识
DOI:10.1097/js9.0000000000003520
摘要

Immune checkpoint inhibitors (ICIs) have revolutionized the management of hepatocellular carcinoma (HCC). Landmark trials, including IMbrave150 and HIMALAYA, have established combination ICI therapies as the standard of care for advanced HCC. Beyond these indications, ICIs are now being explored as neoadjuvant therapies for liver transplantation (LT), offering potential benefits in downstaging tumors and serving as bridging therapies for patients outside traditional transplant eligibility criteria. While early evidence from case reports and trials highlights promising oncologic and survival outcomes, the current understanding of ICI use before LT introduces new, unexplored challenges. Allograft rejection, safety concerns regarding immune-related adverse events, and the effective management of the complex interplay between immunosuppression and immune therapy represent ongoing themes of discussion. The tumor microenvironment and immunomolecular profiles, which critically influence ICI efficacy, remain the true cornerstones of patient stratification that are yet to be fully understood. Additionally, the lack of reliable biomarkers and the limitations of current radiologic criteria complicate treatment planning and response evaluation. Overcoming these obstacles requires multidisciplinary collaboration, refined patient selection strategies, and robust clinical trials to establish the safety and efficacy of ICIs in this context. This review aims to provide an up-to-date summary of the ever-evolving role of ICIs in LT strategies, offering a comprehensive overview of proposed therapeutic protocols, their oncologic and safety profiles, and the integration of emerging biological insights into clinical practice.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Azheng发布了新的文献求助10
1秒前
3秒前
想喝冰豆浆完成签到,获得积分10
3秒前
CodeCraft的应助被一枝清荷采纳,获得10
4秒前
玩家666发布了新的文献求助10
4秒前
要走的路还很长完成签到,获得积分10
4秒前
5秒前
蝈蝈完成签到,获得积分10
5秒前
5秒前
ding的应助被YAM采纳,获得10
6秒前
暴龙战士发布了新的文献求助10
7秒前
mmyhn的应助被白华苍松采纳,获得20
7秒前
传奇3的应助被zht采纳,获得10
8秒前
orixero的应助被超的爱123采纳,获得20
9秒前
9秒前
一YI发布了新的文献求助10
10秒前
意义完成签到,获得积分10
10秒前
优秀含之发布了新的文献求助10
10秒前
赫江涛发布了新的文献求助10
10秒前
好久不见发布了新的文献求助10
11秒前
丘比特的应助被科研通管家采纳,获得10
11秒前
思源的应助被科研通管家采纳,获得10
11秒前
桐桐的应助被科研通管家采纳,获得10
11秒前
wanci的应助被自然白安采纳,获得10
11秒前
12秒前
NexusExplorer的应助被科研通管家采纳,获得10
12秒前
上官若男的应助被科研通管家采纳,获得10
12秒前
12秒前
科研通AI2S的应助被科研通管家采纳,获得10
12秒前
wanci的应助被科研通管家采纳,获得10
12秒前
思源的应助被科研通管家采纳,获得10
12秒前
咖啡不加糖完成签到,获得积分10
12秒前
FashionBoy的应助被科研通管家采纳,获得10
12秒前
英俊的铭的应助被展烨栋采纳,获得10
12秒前
科研通AI6.4的应助被炙热梦曼采纳,获得10
13秒前
水弘的应助被科研通管家采纳,获得10
13秒前
华仔的应助被科研通管家采纳,获得10
13秒前
秋风的应助被科研通管家采纳,获得10
13秒前
酷波er的应助被huzhiying采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193514
求助须知:如何正确求助?哪些是违规求助? 9579686
关于积分的说明 21866883
捐赠科研通 7793152
什么是DOI,文献DOI怎么找? 3437297
关于科研通互助平台的介绍 2560725
邀请新用户注册赠送积分活动 2484176